The Birmingham, England firm hopes to develop a broader test menu with industry partners, using AI and machine learning approaches.

The University of Chicago spinout said that it will use the money to support the commercialization of its saliva-based sequencing test for oral cancers.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

NEW YORK – The US Food and Drug Administration in May granted 510(k) marketing clearances for tests for cancer and precancer disorders, Alzheimer's disease, infectious respiratory diseases, and risk ...

NEW YORK – Osteoporosis diagnostic firm Osteolabs announced Wednesday that it has entered into a strategic partnership with Swiss medical laboratory Labor Team to distribute Osteolabs' test for ...

The protein biomarker-based test will be used to identify patients at high risk of cancer in order to prioritize them for conventional cancer screening methods.

The work will focus on addressing unmet needs in breast cancer, including the diagnosis and treatment of patients with rare cancer subtypes.